Background Invasive lobular breast cancer (ILC) is the second most common type of breast
cancer after invasive breast cancer of no special type (NST), representing up to 15% of all …

Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …

Venetoclax is a B cell lymphoma 2 (BCL-2)–selective antagonist used to treat chronic
lymphocytic leukemia (CLL) and acute myelogenous leukemia (AML). Although this has …

Simple Summary Invasive lobular carcinoma (ILC), the second most common type of breast
cancer, is a distinct entity. Despite their unique biology and clinical course, lobular …

Abstract Programmed death-ligand 1 (PD-L1) expression on the surface of tumour cells can
cause tumour immune evasion. Benefits of combining anti-PD-L1 therapy with nab …

Bromodomain and extraterminal domain (BET) proteins are epigenetic molecules that
regulate the expression of multiple genes involved in carcinogenesis. Breast cancer is an …

Spinal cord injury (SCI) is a destructive neurological disorder that is characterized by
impaired sensory and motor function. Inhibition of bromodomain protein 4 (Brd4) has been …

The deregulation of apoptosis is a key contributor to tumourigenesis as it can lead to the
unwanted survival of rogue cells. Drugs known as the BH3-mimetics targeting the pro …

BET inhibitors (BETi) exert an excellent anti-cancer activity in breast cancer. However, the
identification of new potential targets to enhance breast cancer sensitivity to BETi is still an …

Enhancers are cis-regulatory sequences that fine-tune expression of their target genes in a
spatiotemporal manner. They are recognized by sequence-specific transcription factors …